Omega Therapeutics

General Information

At Omega Therapeutics, our goal is to pioneer a new class of DNA-sequence-targeting, mRNA-encoded therapeutics to fundamentally transform human medicine in the service of patients. Our pioneering OMEGA Epigenomic Programming platform is designed to coopt nature’s universal operating system by harnessing the power of epigenetics, the mechanism for gene control and cell differentiation. We have deciphered the three-dimensional architecture of the human genome and its accompanying regulators, which are organized into distinct and evolutionarily conserved structures called Insulated Genomic Domains, or IGDs. IGDs are the fundamental structural and functional units of gene control and cell differentiation and act as the “control room” of biology.

Employees: 65
Founded: 2016
Contact Information
Address 20 Acorn Park Drive, Cambridge, MA 02140. US
Phone Number 617-949-4360.
Web Address
View Prospectus: Omega Therapeutics
Financial Information
Market Cap $794.3mil
Revenues $0 mil (last 12 months)
Net Income $-37.5 mil (last 12 months)
IPO Profile
Symbol OMGA
Exchange NASDAQ
Shares (millions): 7.4
Price range $17.00 - $17.00
Est. $ Volume $125.8 mil
Manager / Joint Managers Goldman Sachs/ Jefferies/ Piper Sandler
CO-Managers Wedbush Securities
Expected To Trade: 7/30/2021
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change